VPS35 and Parkinson disease: Pharmacological chaperone has been successfully developed to stabilize VPS35/retromer complex, thereby limiting amyloid precursor protein processing.35 As VPS35 reduction is also implicated in PD,13, 21 such stabilizer could prevent AIMP2 accumulation induced by VPS dysfunction and parkin inactivation.